Omarol Tablet
Omarigliptin
25 mg
Drug International Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Omarol Tablet is used for:
Type 2 Diabetes Mellitus
Adult Dose
Oral
Type 2 Diabetes
The usual recommended dose of Omarigliptin is 25mg once weekly as monotherapy or as add-on therapy for optimization of glycaemic control.
The dosage should be reduced to 12.5mg once weekly in patients with severe renal dysfunction and in patients with end-stage renal failure or in those requiring hemodialysis or peritoneal dialysis.
Child Dose
Renal Dose
Severe end-stage kidney failure
Men: Cr?1.9
Women: Cr?1.4
12.5mg once a week
Administration
Contra Indications
Patients with a history of hypersensitivity to components of this drug.
Severe ketosis, diabetic coma or precoma in type 1 diabetes patients.
Severe infection in which glycemic control is desired by insulin injection, before and after surgery.
Patients with severe trauma.
The efficacy and safety of concomitant administration of this drug and insulin preparations have not been studied.
Precautions
Since this drug is mainly excreted by the kidneys therefore dose should be adjusted in patients with severe renal impairment, hemodialysis or peritoneal
dialysis and end-stage renal failure.
Other anti-diabetic drugs (in particular, insulin preparation or sulfonylurea) should be used with caution in combination with Omarigliptin, as they may cause hypoglycemia.
Following patients or conditions which might cause low blood sugar:
1. Pituitary dysfunction or adrenal insufficiency
2. Malnutrition, starvation, irregular dietary intake, lack of dietary intake or debilitated state
3. Intense muscle movement
4. Excessive alcohol intake
5. The elderly
Caution should be taken in patients engaged in aerial work, operation of an automobile.
Precaution must be taken with drugs that enhances the hypoglycemic action (β-blockers, salicylic acid agents, monoamine oxidase inhibitors, etc.).
Blood glucose level should be carefully monitored when using drugs that attenuate the hypoglycemic action
(adrenaline, adrenocorticotropic hormone, thyroid hormone, etc.).
Pregnancy-Lactation
Clinical trials targeting pregnant women have not been performed so its safety cannot be predicted.
Breastfeeding should be avoided.
Interactions
Interaction of Omarigliptin is with the following:
Metformin
Glimepride
Oral contraceptives
Atorvastatin
Adverse Effects
Side effects of Omarigliptin :
Hypoglycemia, acute pancreatitis, bowel obstruction and intestinal obstruction.
Other side effects are: Gastrointestinal problem, constipation, diarrhea, skin and subcutaneous tissue disorders.
Nasopharyngitis may occur. The adverse effects of Omarigliptin drug were well tolerated.
Mechanism of Action
Omarigliptin is a long-acting inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4).
DPP-4 rapidly degrades incretin hormones. Incretins lower blood glucose concentrations in response to a meal by increasing insulin and decreasing glucagonlevels in a glucose-dependent manner. Thus, omarigliptin's mechanism of action (or MOA) augments the action of incretin hormones
Note
Omarol 25 mg Tablet manufactured by Drug International Ltd.. Its generic name is Omarigliptin. Omarol is availble in Bangladesh.
Farmaco BD drug index information on Omarol Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.